Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

Total Live Articles: 381

Nausea and Vomiting in Pregnancy (NVP) & Hyperemesis Gravidarum

RCOG Green-top Guideline No. 69 The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. Last revised: Jun 2025.

NICE CKS Nausea / vomiting in pregnancy. Last revised: Apr 2025.

Background Information

Definition

Nausea and vomiting in pregnancy (NVP): nausea and/or vomiting during pregnancy that begins <16 weeks of gestation, provided no other causes are present

Hyperemesis gravidarum is a severe form of NVP, where nausea and/or vomiting are severe enough to cause:

  • An inability to eat and drink normally, and
  • Strong limitations on daily activities of living

Epideimology

Mild to moderate NVP is very common and can be considered a normal, physiological part of pregnancy. It affects up to 90% of pregnant women.

Mild to moderate NVP does not negatively impact the developing fetus and may even have a protective effect on the pregnancy.

Aetiology

The primary cause of NVP and hyperemesis gravidarum is linked to hypersensitivty to GDF-15 – a vomiting hormone produced when placental genes are activated

  • hCG is no longer believed to be the causative factor
  • GDF-15 is responsible for causing taste aversion, loss of appetite, nausea, vomiting, and weight loss

Key risk factors:

  • Genetic factors (variations affecting the expression of the GDF-15)
  • Previous history of NVP or hyperemesis gravidarum
  • Multiple pregnancies (e.g. twins)
  • Trophoblastic disease (including molar pregnancy and choriocarcinoma)
  • Chronic H. pylori infection

Clinical Features

NVP and hyperemesis gravidarum usually begin at 4-7 weeks of gestation and peak at ~9 weeks. Symptoms usually resolve by 20 weeks (in ~90% women).

Symptoms:

  • Nausea
  • Vomiting
  • Inability to tolerate food and fluids
  • Hypersalivation and spitting

Complications

Metabolic complications

  • Dehydration (e.g. tachycardia, hypotension, tachypnoea, dry lips and mouth, oliguria or anuria)
  • Weight loss
  • Electrolyte imbalance – hyponatraemia, hypokalemia, metabolic hypochloraemic alkalosis
  • Acute kidney injury
  • Nutritional and vitamin deficiencies
    • Vitamin B1 deficiency → life-threatening Wernicke’s encephalopathy
    • Vitamin B6 and B12 deficiency → peripheral neuropathy

Complications of severe vomiting:

  • Retinal haemorrhage
  • Mallory-Weiss tears / oesophageal rupture
  • Pneumothorax / pneumomediastinum
  • Splenic avulsion
  • GORD / oesophagitis, gastritis

Diagnosis

Diagnostic Criteria

NVP and hyperemesis gravidarum are clinical diagnoses, supported by biochemical findings listed below.

Traditionally, hyperemesis gravidarum is characterised by the triad of 1) ≥5% weight loss 2) dehydration 3) electrolyte disturbances

Latest guideline is now considered a clinical diagnosis

  • NVP hyperemesis gravidarum shares the same symptoms, but hyperemesis gravidarum is severe enough to impact daily activities and quality of life 
  • Signs of dehydration are considered a contributory factor to the diagnosis of HG, which is uncommon in typical, uncomplicated NVP

The traditional triad can help identify HG, but is no longer required for diagnosis.

Investigation and Assessment

History and clinical examination should include:

  • Temperature, blood pressure, pulse, oxygen saturation, respiratory rate, and weight
  • Abdominal and neurological examination

Recommended investigations:

  • Urinalysis (if urinalysis indicates UTI → send MSU)
  • Blood tests
    • FBC
    • U&E
    • Blood glucose
  • Ultrasound – to confirm a viable intrauterine pregnancy and assess for multiple pregnancy / trophoblastic disease
  • Consider TFT, LFT, amylase, calcium, phosphate and venous blood gas in refractory cases / history of previous admissions

Biochemical findings and trends:

Test Finding / trends
Urinalysis Ketonuria is often present

RCOG strongly emphasise that ketonuria is NOT an indicator of dehydration and should not be used to assess the severity of NVP or hyperemesis gravidarum.

FBC Raised haematocrit and haemoglobin (from dehydration)
U&E Electrolytes

  • Hyponatraemia
  • Hypokalaemia

Renal function

  • Typically low urea (from reduced oral intake)
  • High urea and creatinine are possible if patient develops AKI
Venous blood gas Hypochloraemia, metabolic alkalosis

Severity Assessment

The Pregnancy-Unique Quantification of Emesis (PUQE) tool can be used to classify the severity:

  • ≤6 = mild
  • 7-12 = moderate
  • 13-15 = severe

Management

Admission Criteria

Inpatient care should be considered if ANY of the following is present:

  • PUQE score ≥13
  • Failed outpatient management

Refer for inpatient management if ANY of the following is present:

  • Inability to tolerate oral intake
  • Clinical dehydration
  • >5% weight loss despite oral antiemetics
  • Presence of co-morbidities (e.g. epilepsy, diabetes, HIV, hypoadrenalism, psychiatric disease)
  • Concerns regarding mental health

Inpatient vs Outpatient Care

Inpatient care should involve:

  • Rehydration with IV 0.9% saline with additional potassium (dextrose is NOT recommended)
  • Thiamine supplementation (oral or Pabrinex®)
  • Thromboprophylaxis with LMWH (alternative: graduated compression stockings)

If inpatient care is not indicated, offer the following conservative care as an outpatinet@

  • Rest as needed
  • Avoid sensory stimuli (e.g. odours, heat, noise)
  • Eat plain biscuits / crackers in the morning
  • Bland, small, frequent protein-rich meals, low in carbohydrate and fat
  • Drink little and often
  • Acupressure (e.g., over P6 point)

Apart from those above, see the anti-emetic therapy section below, which should be offered in both inpatient and outpatinet care.

Anti-Emetic Therapy

Most of the following can be given orally or parenterally (IM / IV / SC); the route of administration depends on outpatient vs inpatient management.

Stepping up anti-emetics:

  • If the patient does not respond to a single antiemetic, the guideline recommends combining drugs from different classes
  • If the 1st line options are ineffective (even after combinations) →  step up by adding 2nd line medications

Many women will require a combination of two or more medications from both the 1st and 2nd line options

1st line options Antihistamines 

  • Cyclizine
  • Promethazine
  • Pyridoxinedoxylamine (Xonvea®)

Phenothiazines:

  • Prochlorperazine
  • Chlorpromazine
2nd line options Ondansetron (very small risk of orofacial clefting in 1st trimester, but should not be discouraged if 1st line failed)

Dopamine antagonists

  • Metoclopramide
  • Domperidone
3rd line options Corticosteroids (IV hydrocortisone or oral prednisolone) – to be used in combination with other antiemetics

References


Share Your Feedback Below

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Be first to accessour QBank

Sign up to receive major guideline updates and early access when we launch.